HARKAITZ BENGOETXEA ODRIOZOLA-rekin lankidetzan egindako argitalpenak (10)

2023

  1. Efficacy of invasive and non-invasive methods for the treatment of Parkinson's disease: Nanodelivery and enriched environment

    International Review of Neurobiology (Academic Press Inc.), pp. 103-143

2021

  1. The effect of 5-HT1A receptor agonists on the entopeduncular nucleus is modified in 6-hydroxydopamine-lesioned rats

    British Journal of Pharmacology, Vol. 178, Núm. 12, pp. 2516-2532

2020

  1. 6-Hydroxydopamine lesion and levodopa treatment modify the effect of buspirone in the substantia nigra pars reticulata

    British Journal of Pharmacology, Vol. 177, Núm. 17, pp. 3957-3974

2019

  1. Effects of adult enriched environment on cognition, hippocampal-prefrontal plasticity and NMDAR subunit expression in MK-801-induced schizophrenia model

    European Neuropsychopharmacology, Vol. 29, Núm. 5, pp. 590-600

  2. Therapeutic potential of cannabinoids as neuroprotective agents for damaged cells conducing to movement disorders

    International Review of Neurobiology (Academic Press Inc.), pp. 229-257

2018

  1. Correction to: Deleterious Effects of VEGFR2 and RET Inhibition in a Preclinical Model of Parkinson’s Disease (Molecular Neurobiology, (2018), 55, 1, (201-212), 10.1007/s12035-017-0733-x)

    Molecular Neurobiology

  2. Deleterious effects of VEGFR2 and RET inhibition in a preclinical model of Parkinson’s disease

    Molecular Neurobiology, Vol. 55, Núm. 1, pp. 201-212

2017

  1. Morphological Changes in a Severe Model of Parkinson’s Disease and Its Suitability to Test the Therapeutic Effects of Microencapsulated Neurotrophic Factors

    Molecular Neurobiology, Vol. 54, Núm. 10, pp. 7722-7735

2015

  1. Topographical Distribution of Morphological Changes in a Partial Model of Parkinson’s Disease—Effects of Nanoencapsulated Neurotrophic Factors Administration

    Molecular Neurobiology, Vol. 52, Núm. 2, pp. 846-858

2014

  1. Increased antiparkinson efficacy of the combined administration of VEGF- and GDNF-loaded nanospheres in a partial lesion model of Parkinson's disease

    International Journal of Nanomedicine, Vol. 9, Núm. 1, pp. 2677-2687